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ABSTRACT
Antigene RNAs (agRNAs) are small RNA duplexes
that target non-coding transcripts rather than
mRNA and specifically suppress or activate gene
expression in a sequence-dependent manner. For
many applications in vivo, it is likely that agRNAs
will require chemical modification. We have
synthesized agRNAs that contain different classes
of chemical modification and have tested their
ability to modulate expression of the human proges-
terone receptor gene. We find that both silencing
and activating agRNAs can retain activity after
modification. Both guide and passenger strands
can be modified and functional agRNAs can
contain 20F-RNA, 20OMe-RNA, and locked nucleic
acid substitutions, or combinations of multiple
modifications. The mechanism of agRNA activity
appears to be maintained after chemical modifica-
tion: both native and modified agRNAs modulate
recruitment of RNA polymerase II, have the same
effect on promoter-derived antisense transcripts,
and must be double-stranded. These data demon-
strate that agRNA activity is compatible with a wide
range of chemical modifications and may facilitate
in vivo applications.
INTRODUCTION
The therapeutic potential of gene silencing by small
interfering RNAs (siRNAs) is widely recognized (1).
siRNA clinical candidates are commonly modiﬁed to
improve their stability, speciﬁcity and potency (2–4).
Modiﬁed siRNAs have been shown to reduce oﬀ-target
eﬀects resulting from the miRNA pathway (5,6), the
innate immune system (7,8) and loading of the wrong
strand (6,9,10). In addition, chemically modiﬁed siRNAs
have been used to deepen our understanding of the mech-
anism of RNAi (11–16) and improve siRNA delivery
(17,18).
Antigene RNAs (agRNAs) are small duplex RNAs that
target gene promoters. Like siRNAs, they are generally
19bp with 2-nt overhangs at the 30-ends. Depending on
target sequence, cell type and basal level of expression,
agRNAs can either silence (19–21) or activate (22–24)
gene expression at the transcriptional level. Like gene
silencing by siRNAs, modulation of gene expression by
agRNAs involves argonaute (AGO) proteins (25,26).
However, instead of targeting mRNA, agRNAs target
non-coding RNA transcripts (ncRNAs) overlapping
gene promoters (27,28). While agRNAs can target either
sense or antisense non-coding transcripts, the agRNAs
discussed in this study target an antisense transcript
overlapping the promoter of the progesterone receptor
(PR) gene (28). Thus the guide strand of these agRNA
duplexes is the sense strand, in contrast to siRNAs, for
which the guide strand is by deﬁnition antisense (i.e. com-
plementary to the mRNA).
agRNAs that activate gene expression could be used to
modulate expression of disease-associated genes whose
upregulation might be beneﬁcial. As with current gene
silencing technology, however, it is likely that any devel-
opment of agRNAs for in vivo use will require chemical
modiﬁcation to improve stability and biodistribution.
In this study we examine the eﬀects of modiﬁed
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over 120 duplexes, we identify several chemically modiﬁed
compounds that retain partial or full activity.
MATERIALS AND METHODS
Double-stranded RNAs
RNAs were synthesized by Alnylam Pharmaceuticals or
SIGMA Custom Products using standard protocols, or
were purchased from Integrated DNA Technologies.
The concentrations of single strands were determined by
measuring their absorbance at 260nm (A260).
Complementary single strands were combined in
equimolar ratios and diluted to 20mM stock solutions in
2.5  phosphate-buﬀered saline. These duplexes were
annealed by heating to 95 C and slowly cooled to room
temperature in a heating block or thermal cycler. Duplex
integrity was tested by a UV thermal melt experiment as
described below. Duplexes were stored at  20 C.
Cell culture
T47D and MCF7 cells (American Type Culture
Collection) were maintained in RPMI-1640 media
(Sigma) supplemented with 10% (v/v) FBS, 0.5 MEM
non-essential amino acids, 0.4 unitsml
 1 bovine insulin,
10mM HEPES and 1mM sodium pyruvate. Cells were
cultured at 37 C and 5% (v/v) CO2.
Lipid-mediated transfection
Cells were plated at 110000–160000 cells per well in
six-well plates (Costar) in RPMI. A higher number of
cells was typically seeded for RNA analysis than for
protein analysis. Transfections were performed after 1–2
days, when the cells had adhered and attained about
20–30% conﬂuence. Lipofectamine RNAiMAX cationic
lipid (1.1ml/well, Invitrogen) and RNA (31pmol/well)
were individually diluted in Opti-MEM (Invitrogen),
then combined and allowed to incubate for 20min
(volume 250ml/well) before pipetting into cell-culture
wells containing 1ml fresh Opti-MEM (ﬁnal volume
1.25ml, 25nM duplex RNA for all transfections except
dose response experiments). The transfection solution
was replaced with RPMI after 24h, and media were
changed again 2 days later. For dose response experi-
ments, the ratio of lipid to RNA was kept constant, and
the concentration of RNA was varied from 0 to 50nM.
For competition experiments, the cells were passaged
into new plates on Days 2 or 3 after transfection. The
second transfection was carried out on Day 4 after the
ﬁrst transfection under identical conditions, and protein
was harvested on Days 7 or 8. The negative control duplex
Neg1 used in these experiments consisted of oligonucleo-
tides 50-UCAAGAAGCCAAGGAUAAUdTdT and 50-A
UUAUCCUUGGCUUCUUGAdTdT.
RNA harvest and quantitative real-time PCR
Total RNA from treated MCF7 or T47D cells was har-
vested 3 days after transfection. After washing with PBS,
TRI reagent (1ml, Sigma) was added to each well,
incubated for several minutes, mixed well and transferred
to a 1.5-ml microcentrifuge tube. Chloroform (250ml) was
added and the mixture was shaken vigorously for 1min,
then centrifuged at 12500rpm for 15min. The clear
aqueous layer was transferred to a new 1.5-ml
microcentrifuge tube, avoiding any of the interphase or
organic layer. Addition of cold isopropanol (500ml)
followed by shaking, incubation at  20 C (at least
10min), and centrifugation (12500rpm, 15min, 4 C)
gave a pellet, which was washed with 75% ethanol,
dissolved in nuclease-free water (20ml), and quantitated
by the A260 of an aliquot (2ml in 200ml TE buﬀer).
Samples of 2mg RNA were removed and treated with
DNase I (Worthington). After heat-inactivation of the
DNase enzyme (75 C, 10min), the samples were reverse
transcribed using random hexamer primers with the High
Capacity cDNA Archive kit (Applied Biosystems).
Quantitative real-time PCR (qPCR) was used to
measure RNA levels with 30–100ng of cDNA (carried
out in triplicate, and repeated for at least two independent
transfections). For analysis of PR mRNA, we used a
primer-probe assay (IDT) consisting of primers 50-CTTA
CCTGTGGGAGCTGTA-30 and 50-GCACTTTCTAAG
GCGACATG-30 as well as probe 50-CTGCCCTTCCAT
TGCCCTCTT-30. For analysis of promoter-derived anti-
sense transcripts, we used SYBRgreen qPCR with primers
50-GGAGGAGGCGTTGTTAGAAA-30 and 50-GAAGG
GTCGGACTTCTGCT-30. Data were normalized to
levels of GAPDH mRNA as determined by a TaqMan
Gene Expression Assay (Applied Biosystems).
Analysis of protein expression
Protein was generally harvested from treated MCF7 or
T47D cells 5 days after transfection. The cells were
washed with phosphate-buﬀered saline (PBS), trypsinized,
transferred to 1.5-ml microcentrifuge tubes and
centrifuged (3500rpm, 15min). The pellets were washed
with cold PBS and gently lysed by addition of 50ml lysis
buﬀer [50mM Tris–HCl (pH 8.0), 120mM NaCl,
0.5%Nonidet P40, 1mM EDTA, 1mM DTT]. Protease
inhibitor cocktail set 1 (Calbiochem) was added to the
lysis buﬀer just before use. After a freeze-thaw cycle to
ensure complete lysis, the lysates were centrifuged to
pellet insoluble cell debris and cell lysate solutions were
transferred to new microtubes. Protein concentrations
were calculated using the BCA assay (Thermo Scientiﬁc).
Western blots were performed on cell lysates (30mg
protein per lane). Proteins were separated by
SDS–PAGE using 7.5% Tris–HCl acrylamide gels, then
transferred onto nitrocellulose membranes. After blocking
the membrane (5% milk in PBS-T) for 1h, the upper
portion of the membrane was treated with PR monoclonal
primary antibody (Cell Signaling, 1:1000 dilution in
PBS-T,  15h) and the lower portion was treated with
anti–b-actin (Sigma, 1:10000 dilution, 1h) as an internal
control. Protein was visualized using HRP-conjugated sec-
ondary anti-mouse (Jackson Immunolabs, 1:5000 for PR
and 1:20000 for actin, 30–45min) The membranes were
then brieﬂy treated with West Pico SuperSignal develop-
ing solution (Thermo Scientiﬁc) before exposing them to
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transfections, of which one representative western blot is
shown.
Determination of melting temperature (Tm)
Annealed siRNA duplexes were diluted to 0.8mM in 0.1M
phosphate buﬀer, pH 7.4 (ﬁnal volume 500ml) and
transferred to quartz cuvettes. The solutions were
topped with mineral oil (200ml) and heated from 18 to
99 Ca t1  C/min while monitoring changes in A260 using
a Cary 100 Bio spectrophotometer. Samples were then
re-annealed in the spectrophotometer and the experiment
was repeated several times. Tm values were calculated as
the ﬁrst derivatives of the plot of A260 vs temperature, and
the results from three experiments were averaged.
Chromatin immunoprecipitation
Chromatin immunoprecipitation (ChIP) was performed
essentially as described (29). Two or three 150-mm
dishes of T47D or MCF7 cells were reverse transfected
with 25nM of native agRNA, modiﬁed agRNA or
luciferase control duplex siGL2 (30).
Media were changed on Day 2 and the cells harvested
on Day3. To crosslink and harvest nuclei, the cells were
treated with 1% formaldehyde in PBS (10ml) for 10min,
then the crosslinking reaction was quenched with glycine
(0.125M ﬁnal concentration, at least 5min). Cells were
collected and nuclei were isolated by treatment with cold
hypotonic lysis buﬀer (4ml) containing 10mM Tris (pH
7.4), 10mM NaCl, 3mM MgCl2 and 0.5% Nonidet P40.
The pelleted nuclei were lysed with a buﬀer containing
1% SDS, 10mM EDTA, 50mM Tris–HCl (pH 8.1) and
1  complete protease inhibitor cocktail (Roche). DNA
was sonicated on ice to an average fragment size
of  500bp. The lysate was then centrifuged to remove
insoluble cell debris and the supernatant precleared
with Protein G Plus/Protein A Agarose suspension
(Calbiochem).
An aliquot of the cleared lysate (100ml) was diluted to
1ml in buﬀer [0.01% SDS, 1.1% Triton X-100, 1.2mM
EDTA, 16.7mM Tris pH 8.1, 167mM NaCl and 1 
complete protease inhibitor cocktail (Roche)]. Mouse
anti-RNAPII IgG (Millipore, Catalogue #05-623,
3–6mg) or normal mouse IgG (Millipore Catalogue
#12-371, 3–6mg) was added and the solution rotated at
4 C overnight. Protein G Plus / Protein A agarose suspen-
sion (30–60ml) was added to precipitate the antibody
complexes and the beads were washed as described (29).
Complexes were eluted using 2 250ml of NaHCO3
(0.1M) containing 1% SDS. NaCl was added (ﬁnal con-
centration 200mM) and the samples heated to 65 C for at
least 2h to reverse crosslinks. The samples were then
treated with RNase A (1ml) at 37 C for 30min, followed
by Tris–HCl (pH 7.0, 20ml), EDTA (0.5M, 10ml) and
proteinase K (20mg) at 42 C for 45min. DNA was
isolated by phenol-chloroform extraction and ethanol pre-
cipitation. Pellets were diluted to 50ml in water and 5ml
was used per qPCR reaction. qPCR primers used at the
PR promoter were Fwd 50-CCTAGAGGAGGAGGCGT
TGT and Rev 50-ATTGAGAATGCCACCCACA. Levels
of RNAPII at the GAPDH promoter were also measured
with primers Fwd 50-TACTAGCGGTTTTACGGGCG
and Rev 50-TCGAACAGGAGGAGCAGAGAGCGA
and were used for normalization. Each sample was
normalized to a corresponding 2% input sample.
Statistics, dose response proﬁles, and curve ﬁtting
Error bars shown on qPCR graphs correspond to
standard deviations from triplicate measurements of at
least two independent transfections; they include the
error from the qPCR measurement as well as from diﬀer-
ences between the transfections. For Figures 2–7 we also
examined whether RNA expression levels were signiﬁcant-
ly diﬀerent from the mismatch control by conducting a
two-tailed unpaired Student’s t-test with equal variances,
and for this test we considered only biological replicates
(using averages of the triplicate qPCR measurements for
each). Signiﬁcance levels of P-values are: *P<0.05,
**P<0.01 and ***P<0.005.
Dose responses were ﬁt to the model equation
y=100[1–x
m/(n
m+x
m)], where y is the percent of target
(protein or mRNA) remaining, x is the concentration of
agRNA in nanomolars. The regression was ﬁt by
optimizing m and n using SigmaPlot 11, and n was taken
as the IC50 value.
RESULTS AND DISCUSSION
Experimental design
We focused on the PR gene because it is a
well-characterized target for agRNAs (20,23,25,28). In
T47D breast cancer cells, which express a high level of
PR, PR expression can be dramatically reduced by
agRNA PR-9 that overlaps the start site from –9 to+10
(20,21). In MCF7 breast cancer cells, which express PR at
a lower basal level, its expression can be increased by
agRNA PR-11 targeting the region from –11 to +8 (23).
PR-11 can also activate gene expression in T47D cells but
activation becomes most apparent when the cells are
grown under conditions that repress basal expression of
PR (23). Whether activation or repression is observed
depends primarily on the basal expression level of PR
and the target sequence of the agRNA.
While PR-9 and PR-11 are benchmark agRNAs used
for most experiments, we also examined other duplexes.
For some modiﬁcations we tested analogs of silencing
agRNA PR-26 (–26 to –8) or activating agRNA PR-22
(–22 to –4) to allow more general insights into gene modu-
lation. To permit comparisons with an RNA that engages
the post-transcriptional silencing pathway, we used
modiﬁed analogs of PR2526, a siRNA that is complemen-
tary to PR mRNA from +2526 to +2544. As negative
control we used MM4, a duplex containing four
mismatches with respect to PR-9. Duplex and single-
stranded oligomers were introduced into cells by
standard transfection protocols using cationic lipid.
Expression was analyzed by western analysis of PR
protein and qPCR of PR mRNA.
We use descriptive compound identiﬁers (Table 1). Each
type of modiﬁed duplex is assigned two uppercase letters.
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passenger strand, while the second letter describes modiﬁ-
cation of the guide strand. A lowercase ‘p’ indicates that
the 50-end of the strand is phosphorylated. For example, a
duplex labeled ‘NpF’ has a native passenger strand and a
guide strand that is phosphorylated and fully modiﬁed
with 20-ﬂuoro (20F-RNA) nucleotides. Passenger strands
are listed above guide strands throughout.
Eﬀects of 20F-RNA modiﬁcation on gene silencing
The structure of 20F-RNA (Figure 1) is similar to that of
RNA (31) but confers resistance to endonucleases (32,33).
For siRNAs, partial modiﬁcation with 20-F RNA is
tolerated throughout either strand of the duplex (34–36)
and there have been reports of functional siRNAs that are
extensively or completely modiﬁed with 20F-RNA
(33,37,38). 20F-RNA has been shown to reduce the
immunostimulatory activity of siRNAs (39,40).
We tested three types of 20F-RNA-modiﬁed strands:
fully modiﬁed (F), modiﬁed at all of the pyrimidine
units (Y), and modiﬁed at positions near the termini (Z)
(Table 1 and Figure 2A). Relative to unmodiﬁed duplex
PR-9, we observed reduced potency when either strand
was replaced with a fully-ﬂuorinated (PR-9NpF,
PR-9pFN) or pyrimidine-ﬂuorinated strand (PR-9NpY,
PR-9pYN) (Figure 2B). siRNA PR2526, by contrast,
retained most silencing activity after total or partial
modiﬁcation of its passenger strand (PR2526pFN,
PR2526pYN) but activity was lost after modiﬁcation
of the guide strand (PR2526 NpF, PR2526 NpY)
(Figure 2B). Duplexes based on either PR-9 or PR2526
containing heavy modiﬁcation in both strands were largely
inactive (Supplementary Figure S1).
Given the loss of activity after aggressive modiﬁcation
of PR-9, we tested more limited terminal substitutions. A
PR-9 analog containing minimal modiﬁcation of the guide
strand was eﬀective when paired with an unmodiﬁed
passenger strand (PR-9NZ) but not when the passenger
strand was heavily modiﬁed (PR-9YZ and PR-9FZ)
(Figure 2C). Analogs of PR2526 containing a minimally
modiﬁed guide strand (PR2526NZ, PR2526YZ,
PR2526FZ) were active regardless of the extent of modi-
ﬁcation of the passenger strand (Figure 2C).
We also examined the eﬀect of 20F-RNA modiﬁcation
on the activity of silencing agRNA PR-26 in an eﬀort to
determine how modiﬁcation eﬀects might vary depending
on the sequence of the agRNA. When the pyrimidines
of either or both strands of PR-26 were replaced
with 20F-RNA (PR-26 YN, PR-26 NY, PR-26 YY),
most silencing activity was retained (Figure 2D). Taken
together, data from PR-9 and PR-26 demonstrate that
20F-RNA substitutions are compatible with the mechan-
ism for agRNA activity but that the activity of individual
patterns of modiﬁcation can vary between duplexes.
Eﬀect of 20F-RNA modiﬁcation on gene activation
We introduced 20F-RNA into activating agRNA PR-11
(Figure 3A) and observed that the modiﬁcation was
broadly tolerated. Modiﬁcation of the pyrimidines of the
passenger strand (PR-11 pYN), total modiﬁcation of the
passenger strand (PR-11 pFN), or heavy modiﬁcation of
the guide strand (PR-11 NpF and PR11 NpY) all led to
gene activation, albeit at levels below those of the unmodi-
ﬁed PR-11 duplex (Figure 3B). Combining the unmodiﬁed
or heavily modiﬁed passenger strands with a minimally
modiﬁed guide strand showed a loss of potency as the
degree of modiﬁcation increased (Figure 3C).
Nevertheless, all of these duplexes retained signiﬁcant
activity (2-fold to 6-fold at the RNA level). PR-11
analogs with both strands heavily modiﬁed were inactive
(Supplementary Figure S2).
To assess the generality of 20F-RNA modiﬁcation, we
also tested a second activating agRNA, PR-22. For
PR-22, 20F-RNA was well-tolerated in the passenger
strand and duplexes PR-22 FN and PR-22 YN were
able to activate gene expression at both RNA and
protein levels without loss of potency (Figure 3D). The
guide strand of PR-22 was more sensitive to 20F-RNA
modiﬁcation, with lower levels of gene activation by
agRNAs PR-22 NY and PR-22 YY. Taken together
with results from PR-11, these results show that
20F-RNA substitutions can be well tolerated by activating
agRNAs and that chemical modiﬁcations on the passenger
strand tend to be better tolerated.
Table 1. Descriptive strand names used throughout this work
Abbreviation Strand chemistry
N Native RNA strand
F2 0F-RNA, fully modiﬁed
Y2 0F-RNA, all pyrimidines
Z2 0F-RNA, contains three units near termini
P2 0-OMe-RNA, all pyrimidines
J2 0-OMe-RNA, two units at the 50-end
L LNA, contains four units distributed evenly
L3 LNA, contains two units toward the 30-end
L5 LNA, contains two units toward the 50-end
p A lower case ‘p’ preceding any strand abbreviation
indicates a 50-phosphate
Figure 1. Chemical modiﬁcations used in this study.
Nucleic Acids Research, 2010,Vol.38, No. 15 5245Figure 2. PR gene expression can be silenced by agRNAs containing 20F-RNA. (A) Duplex sequences: passenger strands are listed on top in all
cases; for siRNA PR2526 this is the sense strand, but for agRNAs PR-9 and PR-26 this is the antisense strand. Modiﬁcation codes: dna, RNA,
20F-RNA; p=phosphate. (B) PR-9 analogs and controls containing one strand heavily or fully modiﬁed with 20F-RNA. (C) PR-9 analogs and
controls containing a minimally 20F-RNA-modiﬁed guide strand. (D) PR-26 analogs containing one or both strands heavily or fully modiﬁed with
20F-RNA. All data are normalized to mismatch control MM4. RNA levels are the average (±SD) from at least two independent transfections.
*P<0.05, **P<0.01, ***P<0.005. Protein levels were also conﬁrmed by at least two independent transfections, from which a typical western blot
is shown.
5246 Nucleic Acids Research, 2010,Vol.38, No. 15Figure 3. PR gene expression can be activated by agRNAs containing 20F-RNA. (A) Duplex sequences: passenger strands are listed on top in all
cases; for agRNAs PR-11 and PR-22 this is the antisense strand. Modiﬁcation codes: dna, RNA, 20F-RNA; p=phosphate. (B) PR-11 analogs
containing one strand heavily or fully modiﬁed with 20F-RNA. (C) PR-11 analogs containing a minimally 20F-RNA-modiﬁed guide strand.
(D) PR-22 analogs containing one or both strands heavily or fully modiﬁed with 20F-RNA. All data are normalized to mismatch control MM4.
RNA levels are the average (±SD) from at least two independent transfections. *P<0.05, **P<0.01, ***P<0.005. Protein levels were also
conﬁrmed by at least two independent transfections, from which a typical western blot is shown.
Nucleic Acids Research, 2010,Vol.38, No. 15 5247Eﬀect of 20-O-methyl-RNA on gene silencing
20-O-Methyl-RNA (20OMe) nucleotides (Figure 1)
improve the thermal and nuclease stability of siRNA
duplexes (41,42). Inclusion of 20OMe-RNA units also
reduces oﬀ-target eﬀects mediated either through the
miRNA pathway (5) or the innate immune system (43–
45). We tested duplex RNAs containing two 20OMe
ribonucleotides at the 50-terminus of each strand (J) or
at all pyrimidine nucleotides (P) (Figure 4A). Duplexes
PR-9 JJ, containing 20OMe nucleotides at both
50-termini, and PR-9 PN, containing 20OMe modiﬁcation
at the pyrimidine nucleotides of the passenger strand, were
both eﬀective gene silencing agents (Figure 4B). Duplexes
containing pyrimidine modiﬁcations on the guide strand
(PR-9NP, PR-9PP) were inactive, consistent with
previous observations that 20OMe modiﬁcation is often
better tolerated in the passenger strand (41). Variants of
PR2526 (PR2526PN, PR2526NP and PR2526PP) had
activities similar to the PR-9 variants (Figure 4B).
We also examined the eﬀects of 20OMe modiﬁcation of
a second silencing agRNA, PR-26, and identiﬁed analogs
that inhibited PR expression (Figure 4C). However, for
PR-26, modiﬁcation of the guide strand in PR-26 NP
did not prevent gene silencing. These data demonstrate
that agRNA-mediated gene silencing can tolerate the
introduction of 20OMe-RNA modiﬁcations. The inﬂuence
of a speciﬁc pattern of modiﬁcation, however, depends on
the identity of the parent sequence and can vary between
agRNAs.
Eﬀect of 20-O-methyl-RNA on gene activation
We introduced 20-O-methyl modiﬁcations into two diﬀer-
ent activating agRNAs, PR-11 and PR-22 (Figure 5A).
Substitution of 20OMe units into PR-11 reduced activa-
tion from 8-fold to 2–3-fold (Figure 5B). PR-11PP with
two heavily modiﬁed strands were the least activating. By
contrast, activation by modiﬁed PR-22 duplexes was rela-
tively stable at 4- to 6-fold regardless of modiﬁcation
Figure 4. PR gene expression can be silenced by agRNAs containing 20OMe-RNA. (A) Duplex sequences: passenger strands are listed on
top in all cases; for siRNA PR2526 this is the sense strand, but for agRNAs PR-9 and PR-26 this is the antisense strand. Modiﬁcation
codes: dna, RNA, 20Ome-rna.( B) PR-9 analogs and controls containing 20OMe-RNA. (C) PR-26 analogs containing 20OMe-RNA. All data
are normalized to mismatch control MM4. RNA levels are the average (±SD) from at least two independent transfections.
*P<0.05, **P<0.01, ***P<0.005. Protein levels were also conﬁrmed by at least two independent transfections, from which a typical western
blot is shown.
5248 Nucleic Acids Research, 2010,Vol.38, No. 15(Figure 5C). These data suggest that, as observed above
for gene silencing, the impact of 20OMe modiﬁcations on
gene activation will vary depending on the parent
sequence.
Eﬀect of LNA on gene silencing
Locked nucleic acid (LNA) (Figure 1) is a rigid nucleotide
analog containing a constrained, bicyclic sugar.
Introduction of locked nucleotides into DNA or RNA
oligomers leads to substantially enhanced aﬃnities for
complementary sequences (46–49) and enhanced resist-
ance to digestion by nucleases (49–51). Several studies
have also shown that the introduction of LNA nucleotides
can improve the properties of siRNAs (9,35,51–53). LNA
has been shown to improve loading of the desired strand
(51), increase nuclease resistance (51) and lower immune
stimulation (53).
We tested a series of duplexes containing four LNA
nucleotides evenly distributed across either the passenger
or guide strand (Figure 6A). PR-9 LN and PR-9 NL both
retained the ability to silence gene expression, albeit to a
lesser extent than PR-9 (Figure 6B). Signiﬁcant silencing
activity was maintained regardless of whether the sense or
antisense strand was modiﬁed.
The high binding aﬃnity of LNA has been used to
direct loading of the appropriate strand into AGO and
bias strand usage (51). We tested a series of
Figure 5. PR gene expression can be activated by agRNAs containing 20OMe-RNA. (A) Duplex sequences: passenger strands are listed on top in all
cases; for agRNAs PR-11 and PR-22 this is the antisense strand. Modiﬁcation codes: dna, RNA, 20Ome-rna.( B) PR-11 analogs containing
20OMe-RNA. (C) PR-22 analogs containing 20OMe-RNA. All data are normalized to mismatch control MM4. RNA levels are the average
(±SD) from at least two independent transfections. *P<0.05, **P<0.01, ***P<0.005. Protein levels were also conﬁrmed by at least two
independent transfections, from which a typical western blot is shown.
Nucleic Acids Research, 2010,Vol.38, No. 15 5249Figure 6. PR gene expression can be silenced by agRNAs containing LNA. (A) Duplex sequences: passenger strands are listed on top in all cases; for
siRNA PR2526 this is the sense strand, but for agRNA PR-9 this is the antisense strand. LNA sequences contain 5-methylcytosine instead of
cytosine. Modiﬁcation codes: dna, RNA, lna.( B) PR-9 analogs and controls containing four evenly distributed LNA units. (C) PR-9 analogs
containing LNA at strand ends. (D) PR2526 analogs containing LNA at strand ends. All data are normalized to mismatch control MM4. RNA
levels are the average (±SD) from at least two independent transfections. *P<0.05, **P<0.01, ***P<0.005. Protein levels were also conﬁrmed by
at least two independent transfections, from which a typical western blot is shown.
5250 Nucleic Acids Research, 2010,Vol.38, No. 15thermodynamically biased LNA analogs, to explore
whether their activities would diﬀer (Figure 6C). Strand
L3 contains LNA at the second and sixth positions from
its 30-end, while strand L5 contains LNA at the second
and sixth positions from its 50-end. Modiﬁcation of the
30-end of the guide strand (PR-9 NL3), reduced activity
of PR-9 (Figure 6C). All other RNA duplexes containing
two LNA substitutions on one strand (PR-9NL5,
PR-9L3N, PR-9L5N) were active regardless of which
strand was modiﬁed or the location of the modiﬁcation.
Some activity was lost when both strands were modiﬁed
with LNA (PR-9 L3L5, PR-9 L5L3). Variants of PR2526
containing LNA bases yield results that were analogous to
LNA-substituted variants of PR-9 (Figure 6B and D).
These results demonstrate that LNA modiﬁcations are
compatible with gene silencing by agRNAs, but show no
evidence for biased strand loading in the context of the
PR-9 or PR2526 sequences. The reduction in activity upon
modiﬁcation of the 30-end of the guide strand (‘NL3’) is
consistent with previous observations that LNA modiﬁca-
tion of the sixth nucleotide from the 30-end of this strand
leads to reduced potency (51). Results were similar for
each pattern of modiﬁcation regardless of whether
agRNA PR-9 or siRNA PR2526 was the parent duplex,
emphasizing that the response of agRNAs and siRNAs to
chemical modiﬁcation can be similar.
Eﬀect of LNA on gene activation
We tested LNA-modiﬁed analogs of PR-11 for gene acti-
vation in MCF7 cells (Figure 7A). For activating duplex
PR-11, we observed activation (2- to 3-fold versus 6-fold
Figure 7. PR gene expression can be activated by agRNAs containing LNA. (A) Duplex sequences: passenger strands are listed on top in all cases;
for agRNA PR-11 this is the antisense strand. LNA sequences contain 5-methylcytosine instead of cytosine. Modiﬁcation codes: dna, RNA, lna.( B)
PR-11 analogs containing four evenly distributed LNA units. (C) PR-11 analogs containing LNA at strand ends. All data are normalized to
mismatch control MM4. RNA levels are the average (±SD) from at least two independent transfections. *P<0.05, **P<0.01, ***P<0.005.
Protein levels were also conﬁrmed by at least two independent transfections, from which a typical western blot is shown.
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strand with four LNA nucleotides (PR-11LN,
PR-11NL) (Figure 7B). The potency was reduced to the
same extent whether the guide or passenger strand was
modiﬁed. For activation by PR-11, all of the thermo-
dynamically biased LNA analogs maintained signiﬁcant
activity (Figure 7C). Modiﬁcation of either end of the
guide strand (PR-11 NL3, PR-11 NL5) gave activity in-
distinguishable from that of the native PR-11. Passenger
strand modiﬁcation (PR-11 L3N, PR-11 L5N) gave a
slight reduction in activation, and modiﬁcation of both
strands (PR-11 L3L5, PR-11 L5L3) led to a further reduc-
tion in activation. Nonetheless, even these duplexes
modiﬁed in both strands gave >3-fold activation at the
RNA level and clear activation at the protein level.
Together with results of 20F and 20-OMe substitution,
these data suggest that agRNA-mediated gene activation
is broadly tolerant of chemical modiﬁcation.
Eﬀect of combining modiﬁcations on gene silencing
Many examples exist of potent and stable siRNAs
containing multiple types of chemical modiﬁcations
(38,54–56). In some cases, combination of multiple modi-
ﬁcations led to potency and stability unattainable by
the individual modiﬁcations alone (54,56). We set out
to explore whether combination agRNA duplexes
(Figure 8A) would yield better gene inhibition or
activation in their respective cell lines. Even if existing
potency is only maintained, the combination of diﬀerent
chemistries could aﬀord better stability and other desir-
able drug properties.
Our criteria for choosing combinations was to select
modiﬁed strands from PR-9 and PR-11 analogs showing
the highest activity and recombine them in new ways. For
PR-9 analogs, this led to the identiﬁcation of several
potent new duplexes (Figure 8B). Duplexes including
PR-9 L5L5, PR-9JL, PR-9 JZ and PR-9 LZ retained sub-
stantial activity. Duplexes PR-9 LL5 and PR-9 PpJ lost
most activity. The eﬀects appear complex and cannot
simply be characterized by considering additive eﬀects
from the individual modiﬁcations. Nonetheless, it
appears that terminal 20F-RNA modiﬁcation (Z) on the
guide strand and LNA modiﬁcation at the 50-end of the
passenger strand (L5) are generally well-tolerated, whereas
20OMe modiﬁcation of all pyridimines (P) on the passen-
ger strand tends to disrupt the activity.
It is noteworthy that two of the most active combin-
ation duplexes also had Tm values that were too high for
us to measure (PR-9 L5L5 and PR-9 JL). It is sometimes
assumed that high Tm values prevent the strand separation
required for siRNA/agRNA activity, but our ﬁndings
conﬁrm that the relationship between Tm and activity is
more complex. This result is consistent with our previous
observation that the limited number of agRNA duplexes
Figure 8. PR gene expression can be silenced by agRNAs containing combinations of modiﬁcations. (A) Duplex sequences: passenger strands are
listed on top in all cases; for agRNA PR-9 this is the antisense strand. LNA sequences contain 5-methylcytosine instead of cytosine. Modiﬁcation
codes: dna, RNA, 20F-RNA, 20Ome-rna, lna; p=phosphate. (B) PR-9 analogs containing combinations of previously identiﬁed active strands. All
data are normalized to mismatch control MM4. RNA levels are the average (±SD) from at least two independent transfections. Protein levels were
also conﬁrmed by at least two independent transfections, from which a typical western blot is shown.
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for predicting the activity of duplex RNAs (23).
We combined modiﬁed strands from active PR-11
analogs to give a new series of activating agRNAs
(Figure 9A). All the combination duplexes based on
PR-11 lost signiﬁcant activity with respect to the unmodi-
ﬁed control. Duplexes containing LNA in the passenger
strand and 20F-RNA at the termini of the guide strand
(PR-11 LZ and PR-11 L5Z) were the best of this series,
but only showed 2- to 3-fold activation at the RNA level
(Figure 9B).
No evidence that single-strands mediate agRNA activity
There have been reports that single-stranded antisense
RNA can lead to inhibition via the RNAi pathway
(12,57,58). In addition, previous work from our lab
(59–61) and others (62–65) has shown that single-stranded
oligonucleotides including peptide nucleic acid (PNA) and
LNA–DNA chimeras were able to bind chromosomal
DNA and repress gene expression at the transcriptional
level.
To explore whether the single-stranded RNAs con-
tained within agRNAs can mediate such eﬀects, we trans-
fected T47D and MCF7 cells with various native and
modiﬁed single strands from functional silencing or
activating agRNA duplexes (Figure 10A). Transfections
were carried out under the same conditions and at the
same concentration (25nM) as duplex RNAs. Results
from both qPCR and western blots demonstrate that
single-stranded agRNA, when transfected alone, had no
eﬀect on silencing or activation of PR gene expression
(Figure 10B and C). These data demonstrate that potent
modulation of gene expression by anti-PR agRNAs
requires the presence of intact duplex RNA regardless of
chemical modiﬁcation. Our data indicate that gene
silencing or activation by the agRNA in our study is not
due (i) to slight excess of one strand, (ii) to degradation of
one strand (prior to incorporation into AGO), or (iii) to
single-strand-mediated oﬀ-target eﬀects. The requirement
for RNA duplexes also provides further evidence that
both native and chemically modiﬁed agRNAs make use
of the RNAi machinery.
Concentration dependence of modiﬁed duplexes
To understand the eﬀect of chemical modiﬁcation on the
potency of agRNAs we examined the dependence of gene
silencing or activation on the concentration of selected
RNAs. We observed that potencies of gene silencing by
modiﬁed agRNAs PR-9 L5N and PR-9 NZ were similar
to parent agRNA PR-9 (Figure 11A, see also
Supplementary Figures S3 and S4). Likewise, potencies
of gene activation by PR-11 pYN and PR-11 pFN were
similar to gene activation by parent agRNA PR-11
(Figure 11B). Thus it is possible to achieve potent,
dose-dependent gene modulation by both activating and
inhibitory chemically modiﬁed agRNAs. For silencing
agRNAs based on PR-9, we calculated IC50 values for
the native duplex and several modiﬁed analogs (Table 2)
(Supplementary Figures S3 and S4). At both the protein
and RNA levels, some of the modiﬁed analogs were of
Figure 9. PR gene expression can be activated by agRNAs containing combinations of modiﬁcations. (A) Duplex sequences: passenger strands are
listed on top in all cases; for agRNA PR-11 this is the antisense strand. LNA sequences contain 5-methylcytosine instead of cytosine. Modiﬁcation
codes: dna, RNA, 20F-RNA, 20Ome-rna, lna.( B) PR-11 analogs containing combinations of previously identiﬁed active strands. All data are
normalized to mismatch control MM4. RNA levels are the average (±SD) from at least two independent transfections. Protein levels were also
conﬁrmed by at least two independent transfections, from which a typical western blot is shown.
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while still active, showed reduced potency (e.g. PR-9 NZ).
Modiﬁed duplexes aﬀect recruitment of RNA
polymerase II
We have previously used ChIP of RNA polymerase II
(RNAPII) [see the supporting information of ref. (28)]
and nuclear run-on assays (25) to show that both silencing
and activating agRNAs aﬀect PR transcription. To inves-
tigate whether chemically modiﬁed agRNAs operate
through the same mechanism as their native counterparts,
we carried out RNAPII ChIP using two active modiﬁed
duplexes (Figure 12). In T47D cells, treatment with either
PR-9 or its modiﬁed analog PR-9 PN led to reduced
occupancy of RNAPII at the PR promoter relative to
cells treated with the luciferase control duplex siGL2
(Figure 12A). In MCF7 cells, treatment with either
PR-11 or the modiﬁed analog PR-11 pYN increased
levels of RNAPII at the PR promoter (Figure 12B). The
ﬁnding that native and modiﬁed duplexes behave similarly
supports the hypothesis that they act through similar
mechanisms.
Native and modiﬁed duplexes have the same eﬀect on
antisense transcript levels
We have previously observed that both activating and in-
hibitory agRNAs bind to an antisense transcript that
overlaps the PR promoter (28). This transcript originates
within PR mRNA and extends 70000-bp upstream. It is
spliced, and the spliced product contains target sequences
for all the agRNAs used in this study. When biotinylated
agRNAs are transfected into cells they bind the antisense
transcript. RNA immunoprecipitation shows that both
activating and silencing agRNAs recruit AGO to the anti-
sense transcript. The antisense transcript, therefore,
Figure 10. Single strands of native or modiﬁed agRNAs are inactive. (A) Sequences: passenger strands are given 50-30, guide strands are given 30-50 as
shown. For these agRNAs the passenger strand is the antisense strand. Modiﬁcation codes: dna, RNA, 20F-RNA, 20Ome-rna, lna; p=phosphate.
(B) PR-9 duplex and native or modiﬁed single-strands. (C) PR-11 duplex and native or modiﬁed single-strands. All data are normalized to the guide
strand of mismatch control MM4. RNA levels are the average (±SD) from at least two independent transfections. Protein levels were also conﬁrmed
by at least two independent transfections, from which a typical western blot is shown.
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agRNAs.
We explored the eﬀect of chemically modiﬁed agRNAs
on levels of the promoter-associated antisense transcript.
We previously observed that treatment of T47D cells with
silencing agRNA PR-9 led to a reduction of antisense
transcript levels, while treatment of MCF7 cells with
activating agRNA PR-11 led to no signiﬁcant change in
antisense transcript levels (28). We repeated these experi-
ments using both the native duplexes and several of the
most active modiﬁed analogs. We monitored expression of
PR mRNA and the antisense transcripts that span the
agRNA target region using qPCR.
Native and modiﬁed duplexes gave comparable results.
PR-9 and modiﬁed PR analogs reduced expression of both
PR mRNA and the promoter-derived antisense transcript
similarly (Figure 13A). Conversely, PR-11 and modiﬁed
analogs increased expression of PR mRNA, but caused no
signiﬁcant change in antisense transcript levels
(Figure 13B). The ﬁnding that native and modiﬁed
duplexes have the same eﬀect on levels of the antisense
transcript supports the conclusion that they act through
similar mechanisms.
Inactive modiﬁed duplexes do not compete for target sites
It is interesting to speculate as to why some patterns of
modiﬁcation cause reduced activity. Inactive agRNAs
could be failing at any of a number of steps: (i) loading
into the RNA-induced silencing complex (RISC), (ii)
cleavage or dissociation of the passenger strand, (iii)
import into the nucleus, (iv) binding of the RNA target,
or (v) execution of the eﬀect (activation or silencing). We
previously observed that inactive native duplexes such as
Figure 11. Sample dose response experiments for both (A) silencing and (B) activation. More dose response experiments for PR-9 analogs are shown
in Supplementary Figures S3 and S4.
Table 2. IC50 values for PR-9 and modiﬁed analogs in T47D cells
a
Silencing
agRNA
Type of
chemistry
IC50 (RNA)
(nM)
IC50 (protein)
(nM)
PR9 native 5.6 12.2
PR9 NZ 20F 18.6 19.6
PR9 JpJ 20OMe 9.4 10.2
PR9 PN 20OMe 12.9 12.6
PR9 NL LNA 6.8 13.2
PR9 L5N LNA 13.3 7.4
aPlots used to derive these data are shown in Supplementary Figures S3
and S4.
Figure 12. ChIP of RNA Polymerase II (RNAPII) shows that both
native and modiﬁed agRNAs operate at the transcriptional level. (A)
Treatment of T47D cells with PR-9 or PR-9 PN leads to reduced oc-
cupancy of RNAPII at the PR promoter relative to cells treated with
control duplex siGL2. (B) Treatment of MCF7 cells with PR-11 or
PR-11 pYN leads to increased occupancy of RNAPII at the PR
promoter relative to cells treated with control duplex siGL2.
Nucleic Acids Research, 2010,Vol.38, No. 15 5255Figure 13. Native and modiﬁed duplexes have the same eﬀect on antisense transcript levels. (A) Treatment of T47D cells with PR-9 and modiﬁed
duplexes leads to a signiﬁcant downregulation of both PR mRNA (left) and the promoter-associated antisense transcript (right). (B) Treatment of
MCF7 cells with PR-11 and modiﬁed duplexes leads to a signiﬁcant upregulation of PR mRNA (left) but no signiﬁcant change in levels of the
promoter-associated antisense transcript (right). *P<0.05, **P<0.01, ***P<0.005.
Figure 14. Inactive modiﬁed duplexes do not compete for target sites. Western analysis showing no competition between native agRNAs and
inactive modiﬁed duplexes applied to cells in two transfections 4 days apart. (A) Native PR-9 silences gene expression equally eﬀectively whether
it is transfected before or after an inactive chemically modiﬁed duplex (or negative control). (B) Native PR-11 activates gene expression equally
eﬀectively whether it is transfected before or after an inactive chemically modiﬁed duplex.
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compete for target sites with the active duplex PR-11 (23).
Thus, treating MCF7 cells with inactive duplex PR-12
prevented gene activation by PR-11 in a subsequent trans-
fection several days later. On the other hand, initial treat-
ment with PR-11 followed later by PR-12 gave activation
comparable to PR-11 alone (23). This experiment showed
that the order of addition is crucial and the duplexes
compete for the same target sites. Duplexes PR-8 and
PR-12 failed at step (v) above—they were loaded into
RISC and even bound the correct RNA target, but
failed to execute an agRNA eﬀect. Therefore, since
shifting the duplex–target interaction by 1–3bp is suﬃ-
cient to eliminate activity, the geometry of interaction at
the promoter may be crucial for induction of gene
activation.
To test where inactive chemically modiﬁed agRNAs
might be deﬁcient we carried out a similar experiment
using two inactive modiﬁed duplexes each for silencing
and activation. In T47D cells we used the inactive
duplexes PR-9 YY and PR-9 pFN. In both cases, levels
of PR expression were identical whether the inactive
duplexes were transfected before or after the active
duplex PR-9 (Figure 14A). Similarly, treatment of
MCF7 cells with PR-11 gave gene activation regardless
of whether the duplexes were transfected before or after
inactive modiﬁed duplexes PR-11 PL and PR-11 LP
(Figure 14B). These data suggest that the modiﬁed
duplexes did not compete for target sites with native
duplexes. Since the inactive modiﬁed duplexes are not
binding the target site, they must be failing at one of the
ﬁrst four steps in the process: RISC loading, passenger
strand removal, nuclear import or target binding.
Furthermore, some of the inactive modiﬁed duplexes
contain native guide strands, thus it seems clear that
they are failing at one of the ﬁrst two steps—RISC
loading or passenger strand removal—since after this
point they would be identical with native duplexes.
Therefore in most cases, the challenges causing modiﬁed
agRNAs to fail are the same as those faced by chemically
modiﬁed siRNAs that are complementary to mRNA.
agRNAs and chemical modiﬁcations
Double stranded RNAs that are complementary to
mRNA are currently being tested in clinical trials (1–4).
Given the success of siRNAs in the laboratory and
progress in the clinic, why would agRNAs enhance the
potential for in vivo application of double-stranded
RNA? One reason is that activating gene expression
would open up a wider range of therapeutic targets and
may provide new opportunities for development. For
example, if more of a protein product is needed to treat
a disease, upregulating expression using agRNAs might
prove advantageous, especially if the protein’s site of
action is intracellular and cannot be accessed by system-
ically administered protein. Even in the case of gene
silencing, where existing siRNA technology often gives
superb results, it is possible that silencing at the transcrip-
tional level may be advantageous for some targets. It is
possible to envision that agRNAs may be more potent in
some cases, produce longer lasting eﬀects, or produce
diﬀerent modulation of isoform expression. Finally,
understanding the eﬀect of modiﬁcations will also
important for future studies of agRNA function in
cultured cells. Potential applications for promoter-
targeted duplex RNAs have been summarized in a
recent review (66).
Our data have several implications for the mechanism
of chemically modiﬁed agRNAs: (i) As with any struc-
ture–function analysis, the most important ﬁnding is
that some designs yield active compounds whereas
others do not; (ii) Two strands are necessary for eﬃcient
action of agRNAs, we observe no silencing or activation
by single strands at the highest concentrations used in this
study; (iii) Activation and silencing show a regular, pre-
dictable dose dependence; (iv) As with siRNAs, optimal
modiﬁcations need to be determined empirically for each
sequence; (v) As with siRNAs, both guide and passenger
strands can be modiﬁed, but modiﬁcations are generally
better tolerated on the passenger strand; (vi) IC50 values
and maximal eﬃcacies of modiﬁed and unmodiﬁed
agRNAs are similar, consistent with the expectation that
they operate by a common mechanism; (vii) Both native
and modiﬁed duplexes aﬀect recruitment of RNAPII, also
consistent with a common mechanism; (viii) Addition of
modiﬁed and unmodiﬁed agRNAs leads to almost identi-
cal changes in antisense transcript levels, again consistent
with a shared mechanism; and (ix) Inactive duplexes do
not compete with active duplexes, suggesting that the
inactive duplexes fail at a step prior to association with
the antisense transcript.
The ﬁnding that agRNAs containing 20F-RNA,
20OMe-RNA, or LNA retain the ability to silence or
activate gene expression is signiﬁcant because it demon-
strates that agRNAs tolerate the introduction of modiﬁ-
cations known to be powerful tools for improving in vivo
properties. For duplex RNAs that are complementary to
mRNA, it is commonly observed that diﬀerent sequences
tolerate diﬀerent chemical modiﬁcations or diﬀerent
patterns of the same chemical modiﬁcation. The interplay
of chemical modiﬁcations with each particular sequence is
the ultimate determinant of duplex potency and duplexes
with optimal properties must be determined empirically.
No universal rules of siRNA modiﬁcation have been de-
veloped because our understanding of the nature of this
interplay is not yet suﬃcient.
Our data on agRNAs suggest the same conclusion. We
have tested two diﬀerent silencing agRNAs, PR-9 and
PR-26, and two diﬀerent activating agRNAs, PR-11 and
PR-22. While both tolerate a wide range of modiﬁcations,
the relative potencies of analogous modiﬁed duplexes
diﬀer. Like siRNAs, we conclude that empirical testing
will be needed to identify agRNAs with the best balance
of properties. While empirical testing may be necessary,
we found that a wide range of modiﬁcations were compat-
ible with gene silencing or activation by an
agRNA-mediated mechanism and we predict that it will
not be diﬃcult to develop active chemically modiﬁed
agRNAs for genes of interest where a parent unmodiﬁed
agRNA has already been identiﬁed.
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